Latest news for Shimamura (OTC:SHAOF) Stock

Shimamura Co Ltd is a Japanese apparel retailer. Its core business is Fashion Center Temura, which has over 1,000 stores and sells items for families, primarily to housewives in their twenties to fifties. Fashion Center Temura focuses on low price private brands. Stores are in residential areas in the suburbs and in large cities, including Tokyo and Osaka. Shimamura has more than 500 stores under other brand names that include Casual and Shoes Avel, Baby/Chilren's Goods Birthday, Chambre, and Divero. The company's stores are primarily in Japan, but it has some brands in Taiwan and Shanghai.

Shimamura Co Ltd

<ul>
<li>Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH)</li>
</ul>

News

ABBV

Reported Saturday, AbbVie Unveils Phase 1b/2 EPCORE NHL-2 Trial Results: Epcoritamab Plus R2 Achieves 96% Overall Response Rate In Relapsed/Refractory Follicular Lymphoma

-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic&nbsp;leukemia (CLL) diagnosis and treatment journeys -CLL is one of the most common leukemias among adults affecting more than 200,000 people in the U.S.1,2

Reported Sunday, AbbVie's Emotional Impact Report Reveals Mental Health Challenges Faced By Diverse CLL Patient Populations At ASH 2024

With U.S. stock futures trading slightly lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) to report quarterly earnings at $4.33 per share on revenue of $3.17 billion after the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Toll Brothers shares rose 0.6% to $155.00 in after-hours trading.</li>
<li>Analysts are expecting Casey&#8217;s General Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) to post quarterly earnings at $4.29 per share on revenue of $4.02 billion. The company will release earnings after the markets close. Casey&#8217;s shares climbed 0.5% to close at $422.27 on Friday.</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares climbed in after-market hours trading on Friday after the company received an extension from Nasdaq to file its overdue annual and quarterly reports by Feb. 25. Super Micro Computer shares surged 8.7% to $47.75 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>After the markets close, MongoDB, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) is projected to post quarterly earnings at 69 cents per share on revenue of $497.76 million. MongoDB shares gained 0.8% to $345.99 in the after-hours trading session.</li>
<li>Analysts expect Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) to post quarterly earnings at $1.48 per share on revenue of $14.11 billion after the closing bell. Oracle shares gained 0.9% to $193.35 in after-hours trading.</li>
</ul>
Check This Out:
<ul>
<li> <a href="https://www.benzinga.com/markets/24/12/42380712/how-to-earn-500-a-month-from-oracle-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Oracle Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

CASY

ORCL

SMCI

Toll Brothers, Oracle And 3 Stocks To Watch Heading Into Monday

<ul>
<li>Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapy</li>
<li>Phase 2 study in MF anemia has been initiated, enrolling a broad range of patient types</li>
</ul>

IRON

Reported Sunday, Disc Medicine Shares Phase 1b Results For DISC-0974 In Myelofibrosis Patients At ASH 2024, Starts Phase 2 Trial

-- Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months --
-- No delayed neurotoxicities have been observed to date with anito-cel, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome in more than 150 patients dosed across the Phase 1 and iMMagine-1 studies --
-- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached --
-- Company highlights additional presentations during the ASH Annual Meeting --

ACLX

Reported Sunday, Arcellx Unveiled New Data From Immagine-1 Study In Relapsed/Refractory Multiple Myeloma At The 66th ASH Annual Meeting And Exposition

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54163549&amp;newsitemid=20241208030033&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=b1f34df05794f55066bb0d7455bf5c26">PureTech Health plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, presented data from the dose escalation phase of its ongoing Phase 1b trial evaluating LYT-200, a first-in-class anti-galectin-9 monoclonal antibody, in patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego, California.
LYT-200 is currently being evaluated both as a monotherapy and in combination with the standard-of-care venetoclax and hypomethylating agents (HMA) for patients whose disease is relapsed/refractory to at least one line of prior treatment. It targets galectin-9, a glycan-binding protein that is significantly upregulated in AML and MDS and plays a key role in disease development, progression, immune interference and drug resistance. Initial results show a favorable safety profile across both arms and all dose levels with no dose limiting toxicities, as well as evidence of response, hematological improvement and sustained disease management.
"Relapsed/refractory acute myeloid leukemia is one of the most dire cancer diagnoses, with 50% of patients non-responsive to or relapsing after initial treatment and a median survival time of less than six months,2" said Luba Greenwood, J.D., Entrepreneur-in-Residence at PureTech who is leading the Gallop Oncology work. "We are encouraged to see that LYT-200 achieved responses as well as long-term disease stabilization in heavily pre-treated patients, and we look forward to progressing LYT-200 as a critical therapeutic option with the potential to treat most AML patients."
In the monotherapy arm, patients received LYT-200 at five dose levels (2.0 mg/kg to 16.0 mg/kg). Across all dose levels, LYT-200 induced clinical benefit and responses in heavily pre-treated, relapsed/refractory AML/MDS patients, even in those with complex cytogenetics and mutations such as KRAS, NRAS, BRAF as well as patients previously fully refractory to standard of care. Out of 22 evaluable patients who received monotherapy, 59% achieved stable disease or better with two partial responses. The mean duration on treatment is greater than two months, which exceeds the standard overall survival of approximately 1.7 months in venetoclax/HMA-refractory patients.3
When administered in combination with venetoclax/HMA, results demonstrate that LYT-200 may enhance the efficacy of standard-of-care therapies, even in relapsed or refractory patients. In the combination arm, patients received LYT-200 across three dose levels (4.0 mg/kg to 12.0 mg/kg) with venetoclax/HMA. Out of 15 evaluable patients who received combination therapy, 80% achieved stable disease or better, with two experiencing complete responses and one patient achieving a morphologic leukemia free state (MLFS).1 The combination regimen has also demonstrated clinical benefit in patients with KRAS/NRAS mutations and the mean duration on treatment up until the point of data cut-off is greater than two months.

PRTC

PureTech Health Presents Promising Data on LYT-200 for Treating Relapsed Leukemia and Blood Disorders at 2024 ASH Annual Meeting

Key Highlights for November 2024:
<ul>
<li>Bitcoin Production: HIVE mined 103 BTC, bringing its HODL portfolio to 2,713 BTC, a 67% increase year-over-year.</li>
<li>Mining Capacity: Maintained an average mining capacity of 5.3 Exahash per Second ("EH/s") with fleet efficiency at 22.3 Joules per Terahash ("J/TH"), reaching a peak hashrate of 5.7 EH/s.</li>
<li>Operational Efficiency: Achieved an average daily production rate of 3.42 BTC, equivalent to 19.3 Bitcoin per Exahash.</li>
<li>Bitcoin Valuation: HIVE's Bitcoin holdings were valued at over $261 million as of November 30, 2024, based on a BTC closing price of approximately $96,400.</li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

HIVE

HIVE Digital November 2024 Production Results: Bitcoin Holdings Values At $261M, Mining Capacity Reaches 5.3 EH/s

<a href="https://www.globenewswire.com/Tracker?data=AqfvHp3-Z_Vxi-A4D-uv1FjI6HBmWssLmlKuTd0X8ZTLm6yMmMN0uXGUuwc8yG57nVqDxFLXQmthERBOs9WGf-j6XvyRGzYbJ_8UudWcyOPX242p-Th79Bfk-UVGaz1qLDiRWUvjUlA0IkivDYspiua-bBerxW1jZZJ4C_DiPScIur6V5Sj0VejM3QGJCnXN4aD2ITyXA_Pe0kHjNa4Ei1E2Gt3vUEPuspu9_0DYq9oQhqM_pSkxxDipSJJx-Pt0ph1xnnawsL-WI0R9u1C-OYpZ5lt2Dkrmlu8TXo0_nwfrIWybITI2xGAfGwFyMoY86llCqF48JLOv6wlmtsS9oqwc9hReZgBNK2H7humQABjh08Em7s4lrCSY6w-iPuYW">MaxCyte, Inc.</a>, (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>, LSE: MXCT))), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This "bottom-up" review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations, the company made adjustments to its workforce which affected 21 positions, reflecting approximately 15% of its personnel globally, including both directly employed individuals and those engaged through third-party employer-of-record (EOR) arrangements. This adjustment is designed to improve accountability, better align personnel resources with the company's goals, and position MaxCyte for long-term growth.
Anticipated cost savings in 2025 as a result of this action are expected to be about $5.8 million. These savings will help accelerate new strategic initiatives addressing customer needs in cell engineering and manufacturing adjacent to electroporation in the cell therapy manufacturing process. Following this adjustment, combined with other personnel decisions made throughout the year, MaxCyte expects to end the year with 116 employees, compared with 143 employees at the end of 2023 (in each case, inclusive of individuals employed through EOR arrangements).
Reflecting the company's strengthened operational foundation and continued strong performance, MaxCyte is raising its full-year 2024 core revenue guidance to project 6% to 8% growth compared to 2023.
"2024 has been a good year for MaxCyte. We signed six SPL agreements, added a cell therapy industry veteran to the board and outperformed our financial commitments to the investment community. Throughout the year, we have implemented a more focused, and accountable, operating philosophy at MaxCyte, taking important and necessary steps to drive innovation and growth in a capital efficient manner," said Maher Masoud, President and CEO at MaxCyte. "I would like to thank the employees impacted by today's announcement for their contributions to MaxCyte. Core business momentum remains strong as we exit 2024, resulting in an increase to our core revenue growth guidance. I am incredibly optimistic about the future of MaxCyte and am excited about the opportunities ahead to drive the cell therapy industry forward."
2024 Revenue Guidance
MaxCyte increases 2024 revenue guidance for core business revenue and affirms SPL Program-related revenue guidance.
MaxCyte now expects full year 2024 core business revenue of 6% to 8% growth compared to 2023. SPL Program-related revenue is expected to be approximately $6 million. The outlook for the full year does not include SPL Program-related revenue from Vertex/CRISPR's CASGEVY&#x2122;.
MaxCyte continues to expect to end 2024 with approximately $185 million in cash, cash equivalents and investments.

Guidance

MXCT

MaxCyte expects FY24: Core Revenue Growth Of 6%-8% (Prior At Least 5%) YoY; Reiterated SPL Revenue ~$6M, To Let Go Of 21 Employees To Save $5.8M In Costs For 2025

<ul>
<li>Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas</li>
</ul>

IPHA

Innate Pharma's TELLOMAK Phase 2 Trial: Lacutamab Demonstrates Significant Symptom Relief and Quality-of-Life Improvements In Advanced CTCL, Presented At ASH 2024

Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NSCLC) with disease progression on or after treatment with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.
Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and AstraZeneca (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>).
The U.S. Food and Drug Administration (FDA) BTD is designed to accelerate the development and regulatory review of potential new medicines that are intended to treat serious conditions and address significant unmet medical needs. The medicine needs to have shown encouraging preliminary clinical results that demonstrate substantial improvement on a clinically significant endpoint over available medicines.
The FDA granted this BTD based on data from the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT04484142%3Fterm%3Dtropion-lung05%26rank%3D1&amp;esheet=54163228&amp;newsitemid=20241206314659&amp;lan=en-US&amp;anchor=TROPION-Lung05&amp;index=1&amp;md5=bfb7eb5703ca3e73e32cb6f616580ed8">TROPION-Lung05</a> phase 2 trial with supporting data from the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04656652&amp;esheet=54163228&amp;newsitemid=20241206314659&amp;lan=en-US&amp;anchor=TROPION-Lung01&amp;index=2&amp;md5=10ce6b41534181dc3781ed4177a115e8">TROPION-Lung01</a> phase 3 trial. Results from a pooled analysis of patients with previously treated EGFR-mutated NSCLC in these studies were <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.daiichisankyo.com%2Ffiles%2Fnews%2Fpressrelease%2Fpdf%2F202412%2F20241206_E.pdf&amp;esheet=54163228&amp;newsitemid=20241206314659&amp;lan=en-US&amp;anchor=presented&amp;index=3&amp;md5=6b0b3b2dfbe52c68b2743eeff561dd40">presented</a> this month at the European Society of Medical Oncology (ESMO) Asia 2024 Congress. This is the first BTD for datopotamab deruxtecan and the twelfth BTD across Daiichi Sankyo's oncology pipeline.

Government

Regulations

Datopotamab Deruxtecan Receives FDA Breakthrough Therapy Designation for EGFR-Mutated Lung Cancer

Summary of the Transaction
<ul>
<li>Boliden has entered into a definitive agreement to acquire the mines Somincor-Sociedade Mineira de Neves-Corvo, S.A. ("Neves-Corvo") and Zinkgruvan Mining Aktiebolag ("Zinkgruvan") for an upfront cash consideration corresponding to USD 1,300 m plus a contingent payment up to USD 150 m, on a cash and debt-free basis (the "Transaction").</li>
<li>The Transaction has a strong industrial logic and strategic fit, complementing current&nbsp;Boliden operations with two well-invested mines. Following the Transaction, zinc and copper concentrate production will increase from 35% to 70% of zinc smelting capacity and 30% to 40% of copper smelting capacity.</li>
<li>The Transaction will lead to a significant increase in production of metals in concentrate in Business Area Mines, by 95% for zinc and 43% for copper, based on 2023 production figures.</li>
<li>The Transaction is expected to be immediately accretive to&nbsp;Boliden's earnings per share from completion of the Transaction and contribute with &gt;10% to Cash EPS1).</li>
<li>The EBITDA contribution from the&nbsp;Neves-Corvo and Zinkgruvan mines over the next five years is estimated to amount to USD 300-350 m annually, assuming consensus prices and terms.</li>
<li>The upfront cash consideration will be fully financed through a bridge loan, which is expected to be refinanced through a share issue corresponding to approximately half of the bridge loan (the "Share Issue"), and the remaining amount in medium and long-term debt financing. The Share Issue will be based on an authorization from a general meeting or subject to approval by a general meeting. Boliden intends to explore options to conduct the Share Issue either as a directed share issue or as a fully underwritten rights issue. The Share Issue is expected to be carried out during the first half of 2025; however no decision has been taken at this time and the timing of the Share Issue is subject to, among other, prevailing market conditions at the time of the Share Issue.</li>
<li>Completion of the Transaction is expected during mid-2025, subject to regulatory approvals, including merger control filings and approvals and other customary closing conditions.</li>
</ul>

BDNNY

LUNMF

Lundin Mining Sells Neves-Corvo And Zinkgruvan Mines To Boliden AB For Up To $1.52B

The company is also expanding the coed Apple Foundation Program to enhance learning opportunities for more students at the Apple Developer Academy
Apple&#xAE; today announced plans to expand in the Kingdom of Saudi Arabia, starting with the launch of the Apple Store&#xAE; online in summer 2025. The online store will bring customers across Saudi Arabia new ways to shop Apple's full range of products, with exceptional service and support directly from Apple in Arabic for the very first time.
Starting in 2026, Apple will begin opening the first of several flagship Apple Store locations in Saudi Arabia. These retail stores will offer customers in the country even more ways to connect with Apple's knowledgable team members and find the perfect products and services. As part of this expansion, Apple is in the initial stages of planning an iconic retail store coming to Diriyah, a UNESCO World Heritage site.

AAPL

Reported Earlier, Apple Expands In Saudi Arabia: Flagship Stores, Developer Training, And Economic Growth

Renowned stock picker and founder of asset management giant Ark Invest, Cathie Wood, deemed Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) breach of the $100,000 mark a "big deal" on Sunday, hailing the leading cryptocurrency's rising prominence in the world of finance and investing.
What happened: In a video shared on X,&nbsp; Wood recalled how Ark Invest published a Bitcoin whitepaper back in 2015 when the asset was valued at just around $250.
Wood remembered her early lessons from renowned economist Arthur Laffer in collaboration with whom Ark released the whitepaper.&nbsp;
"I said to Arthur that sounds like a big idea. How big could it be? And he said at that time, ‘Well, how big is the U.S. monetary base? That's the reserve currency of the world. This seems to be the new reserve currency of the world.'"
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin hit $100K this week. Its emergence signals a shift in the foundation of financial tech. <a href="https://twitter.com/CathieDWood?ref_src=twsrc%5Etfw">@CathieDWood</a> explores its rise and how tech-driven deflation could transform the economy in "In The Know." Past performance does not guarantee future results.<a href="https://t.co/Qqcnc7AyFl">https://t.co/Qqcnc7AyFl</a>
&mdash; ARK Invest (@ARKInvest) <a href="https://twitter.com/ARKInvest/status/1865910532277989559?ref_src=twsrc%5Etfw">December 9, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Wood emphasized that, in addition to being perceived as the next reserve currency, Bitcoin might be viewed in a variety of different ways.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42331483/michael-saylors-bitcoin-strategy-drives-microstrategys-490-surge-hedge-fund-cio-says-its-an-extreme-example-of-volatility-monetization">Michael Saylor&#8217;s Bitcoin Strategy Drives MicroStrategy&#8217;s 490% Surge, Hedge Fund CIO Says It&#8217;s An &#8216;Extreme Example&#8217; Of Volatility Monetization</a>
"It&#8217;s a substitute for gold, a store of value," Wood stated. She also called the asset an "insurance policy" in emerging markets for populations who are used to corruption, collapses in currencies, and outright confiscation of wealth or capital controls.
Wood viewed Bitcoin as an ideal hedge against any form of uncertainty that could affect high-net-worth individuals.
"All fiduciaries have to look at this new asset class, and so we think it could become, you know, 2 to 5 or 6% of portfolios," the veteran investor added.
Why It Matters: CEO Wood has previously <a href="https://www.benzinga.com/startups/24/07/39865003/bitcoin-could-soar-5-837-by-2030-according-to-cathie-wood-why-that-is-a-bold-prediction">expressed bullish sentiments about Bitcoin</a>, predicting a potential surge to a per-unit price of $3.8 million by 2030. Although not impossible, it's unlikely for BTC to achieve these numbers any time soon.
Wood has also joined the call for a<a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41799045/ark-invests-cathie-wood-joins-call-for-strategic-bitcoin-reserve-gives-thumbs-up-to-cynthi"> strategic Bitcoin reserve</a>, which President-elect Donald Trump advocated for during his campaign trail.
Ark Invest was among the handful of players that launched a spot Bitcoin exchange-traded fund, namely ARK 21Shares Bitcoin ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>), earlier this year. As per SoSo Value, it was the <a href="https://sosovalue.com/assets/etf/us-btc-spot">fourth-largest</a> Bitcoin fund as of this writing.
Price Action: As of this writing, Bitcoin was trading at $99,438.47, down 0.16% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42356727/peter-schiff-challenges-jim-cramers-bullish-bitcoin-take-says-such-statements-are-made-at-market-tops">Peter Schiff Questions Jim Cramer&#8217;s Bullish Bitcoin Take As It Slumps From $100K: These Are Statements &#8216;Made At Market Tops</a></li>
</ul>

$BTC

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Ark Invest's Cathie Wood Hails Bitcoin's $100K Climb As A 'Big Deal,' Labels Apex Crypto As Gold Substitute And Emerging Reserve Currency

The Republican party&#8217;s win in the 2024 elections could pave the way for significant policy changes, according to Morgan Stanley. The global financial services firm anticipates growth and innovation, particularly in the <a href="https://www.benzinga.com/24/11/42158682/donald-trumps-win-positive-for-financials-energy-sector-as-pro-growth-effects-will-outweigh-inflationary-pressures-says-analyst">technology </a>and <a href="https://www.benzinga.com/money/best-natural-gas-stocks">natural gas</a> sectors. However, it also cautions that concerns over trade tariffs, immigration policies, fiscal sustainability, and the scope and timing of new policies may constrain the broader economic outlook.
Morgan Stanley&#8217;s Picks
Markets have reacted positively to President-elect Donald Trump&#8216;s victory and have been trading higher than the pre-election levels. However, slower-than-expected deregulation and shallower tax cuts could impact the markets, Morgan Stanley's Global Investment Office believes investors should keep an eye on the following areas:
Energy As per Morgan Stanley, the energy sector faces a divided future. Trump&#8217;s deregulation could benefit traditional energy, but oil&#8217;s outlook is uncertain due to potential oversupply and weak global demand, especially from China. In contrast, natural gas may see growth from strong European demand and increased domestic use for electrification and AI-powered data centers. The clean energy sector could face challenges, if Trump rollbacks Biden&#8217;s 2022 Inflation Reduction Act tax credits. But a full repeal seems unlikely due to the benefits for Republican states.
Invesco S&amp;P 500 Equal Weight ETF (ACRA: RSP) has risen by 17.36% on a year-to-date basis. While, the iShares Russell 1000 Value ETF (ACRA: IWD) and Vanguard High Dividend Yield Index ETF (ACRA: VYM) advanced by 18.56% and 18.96%, respectively, in the same period, underperforming the S&amp;P 500 on a year-to-date basis, which has grown by 28.41% in the same period. Whereas, ProShares S&amp;P 500 Ex-Energy ETF (ACRA: SPXE) grew by 28.85% year-to-date, outperforming the index.
Also read: <a href="https://www.benzinga.com/24/11/42158682/donald-trumps-win-positive-for-financials-energy-sector-as-pro-growth-effects-will-outweigh-inflationary-pressures-says-analyst">Donald Trump&#8217;s Win Positive For Financials, Energy Sector As &#8216;Pro-Growth Effects Will Outweigh Inflationary Pressures,&#8217; Says Analyst</a>
Defense U.S. <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42369000/booz-allen-and-palantir-partner-to-drive-us-defense-operations">defense</a> spending is expected to stay robust amid rising geopolitical tensions, says Morgan Stanley. However, European defense stocks have outperformed U.S. ones due to uncertainty about U.S. NATO involvement and increased spending by other NATO members.
Trump during his first post-election network interview with NBC News on Sunday said &#8220;If they&#8217;re paying their bills, and if I think they&#8217;re treating us fairly, absolutely, I would stay with NATO.&#8221;
Moreover, technological advancements in cybersecurity, AI, drones, and other areas are also favoring smaller, specialized companies over traditional defense giants, added Morgan Stanley.
As per the <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data, the S&amp;P 500 Aerospace &amp; Defense Industry Index has risen by 15.78% year-to-date, whereas Lockheed Martin Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), RTX Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) and iShares U.S. Aerospace &amp; Defense ETF (ACRA: ITA) have grown by 12.48%, 38.45% and 20.15%, respectively in the same period.
Also read: <a href="https://www.benzinga.com/markets/24/12/42317289/ray-dalios-bridgewater-adds-broadcom-apple-smci-in-q3-while-offloading-stake-in-ai-giant-nvidia-and">Ray Dalio&#8217;s Bridgewater Adds Broadcom, Apple, SMCI In Q3, While Offloading Stake In AI Giant Nvidia And Other Big Tech Companies</a>
Technology And Communication According to Morgan Stanley, the technology sector may see mixed outcomes. Cryptocurrencies and AI industries could benefit from Trump&#8217;s favorable stance. Whereas investments in reshoring semiconductors through the CHIPS Act may strengthen those areas, highlighting AI as a national security priority. However, social media and information companies may continue facing regulatory and antitrust challenges.
Major AI payers in the U.S. stock markets include Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a 195.7% year-to-date performance and Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) 19.6% growth in the same period. Whereas, Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) rose by 51.42% and 26.46% year-to-date, respectively.
Photo Courtesy: Shutterstock.com
Read next: <a href="https://www.benzinga.com/24/12/42283257/charles-schwab-goldman-sachs-invesco-add-mara-holdings-morgan-stanley-cuts-stake-here-is-what-changed-with-mara-holdings-in-q3">Charles Schwab, Goldman Sachs Boosts MARA Stake As Stock Rallies 30% In Past 6 Months: Morgan Stanley, Other Major Funds Trim Positions In Q3</a>

Equities

AMZN

GOOG

iShares Dow Jones US Aerospace & Defense Index Fund

MSFT

NVDA

Rydex ETF Trust Rydex S&P Equal Weight ETF

SPXE

Morgan Stanley Narrows Down Winning And Losing Bets In The First 100 Days Of Trump Administration

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares surged past $400 in Robinhood Inc.&#8216;s overnight trading service, reaching $401.16 as of 12:11 am EST Monday in New York, approaching its all-time high of $407.36 set in November 2021. 
What Happened: The electric vehicle maker&#8217;s stock has seen remarkable momentum, closing Friday at $389.22, up 5.34%.
The surge follows a wave of bullish analyst reports, led by Bank of America Securities raising its price target to $400 from $350 while maintaining a &#8220;buy&#8221; rating. BofA Senior Automotive Analyst John Murphy cited a recent visit to Tesla&#8217;s Texas gigafactory and experience with the company&#8217;s Full Self-Driving <a href="https://www.benzinga.com/24/12/42358854/multiple-analysts-hike-price-target-on-tesla-days-after-bear-turned-bullish">version 13.2 as key factors</a>.
See Also: <a href="https://www.benzinga.com/24/12/42382569/elon-musk-asks-was-it-ever-not-a-lie-as-he-accuses-openai-of-selling-out-to-microsoft-and-betraying-its-founding-mission">Elon Musk Asks &#8216;Was It Ever Not A Lie&#8217; As OpenAI Plans To Drop AGI Clause In Microsoft Deal</a>
Why It Matters: Last week, longtime Tesla bear Craig Irwin of Roth MKM <a href="https://www.benzinga.com/24/12/42285783/tesla-bear-craig-irwin-turns-bullish-increases-price-target-from-85-to-380">upgraded the stock</a> to &#8220;buy&#8221; from &#8220;neutral,&#8221; dramatically raising his price target to $380 from $85. &#8220;I don&#8217;t see very many negative catalysts&#8230; Bias is now to the upside, not the downside,&#8221; Irwin stated.
However, not all analysts share the optimism. Guggenheim maintained its &#8220;sell&#8221; rating while lifting its target to $175 from $156. According to Benzinga Pro, Tesla&#8217;s <a href="https://www.benzinga.com/quote/TSLA/analyst-ratings">consensus price target</a> stands at $248.56, based on 34 analyst ratings, ranging from Stifel&#8217;s high of $411 to GLJ Research&#8217;s low of $24.86.
The stock&#8217;s current valuation reflects a price-earnings ratio of 106.72, with shares trading well above their 52-week low of $138.80. Analysts are particularly focused on Tesla&#8217;s planned launch of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42319796/tesla-analyst-lowers-q4-delivery-estimate-says-2-dynamics-will-determine-ev-stocks-valuation">a lower-cost EV model next year</a> and the continued development of its Optimus humanoid robot project.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/09002051/Screenshot-2024-12-09-at-10.49.58%E2%80%AFAM-1024x378.png" alt="" class="wp-image-682370" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42382407/ripple-ceo-brad-garlinhouse-admits-204m-crypto-super-political-action-committee-wouldnt-exist-if-gary-gensler-hadnt-been-the-sec-chair">Ripple CEO Brad Garlinghouse Admits $204M Crypto Super PAC Wouldn&#8217;t Exist If Gary Gensler Wasn&#8217;t The SEC Chair</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Global

TSLA

Tesla Stock Hits $400 In Overnight Trading On Robinhood Amid Analyst Upgrades And FSD Optimism

Macro Economic Events

Econ #s

Economics

Reported Earlier, China Producer Price Index (YoY) For November -2.5% Vs. -2.8% Est.; -2.9% Prior

Reported Earlier, China Consumer Price Index (YoY) For November 0.2% Vs. 0.5% Est.; 0.3% Prior

Reported Earlier, China Consumer Price Index (MoM) For November -0.6% Vs. -0.4% Est.; -0.3% Prior

Reported Earlier, Australia Building Approvals (MoM) For October 4.2% Vs. 4.2% Est.; 5.8% (Revised) Prior

BBJP

WisdomTree Trust Japan Total Dividend Fund

Reported Earlier, Japan Gross Domestic Product (GDP) Price Index (YoY) For Q3 2.4% Est.; 2.5% Est.; 3.2% Prior

SHIMAMURA Co (JP:8227) has released an update. SHIMAMURA Co., Ltd. reported a modest increase in its financial performance for the three months end...

SHIMAMURA Co. Sees Steady Growth in Q1 2024

SHIMAMURA Co (JP:8227) has released an update. SHIMAMURA Co., Ltd. reports a 4.3% increase in net sales and a 5.5% increase in profit attributable ...

Comments

Shimamura

News

Latest news for Shimamura (OTC:SHAOF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga